Verona to raise £14m to go it alone in niche COPD indication
This article was originally published in Scrip
Executive Summary
UK-based Verona Pharma plans to raise £14m, which the company believes will be enough to complete several clinical trials with its lead COPD candidate, RPL554. The fundraising is part of the company's plan to commercialize the drug without a partner in a niche hospital setting.